Roth Capital Downgrades Cyclacel Pharmaceuticals (CYCC) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Nasdaq, S&P 500 slip from record highs as yields and oil rebound
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 66
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 66
Join SI Premium – FREE
Roth Capital downgraded Cyclacel Pharmaceuticals (NASDAQ: CYCC) from Buy to Neutral with a price target of $1.00.
For more ratings news on Cyclacel Pharmaceuticals click here and for the rating history of Cyclacel Pharmaceuticals click here.
Shares of Cyclacel Pharmaceuticals closed at $0.73 yesterday.
For more ratings news on Cyclacel Pharmaceuticals click here and for the rating history of Cyclacel Pharmaceuticals click here.
Shares of Cyclacel Pharmaceuticals closed at $0.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Siam Commercial Bank (SCB:TB) (SMUUY) to Underweight
- Nomura/Instinet Downgrades Workman Co Ltd (7564:JP) (WKISF) to Neutral
- Leerink Downgrades Caribou Biosciences Inc. (CRBU) to Market Perform
Create E-mail Alert Related Categories
DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
